Key points are not available for this paper at this time.
The glomerular disease IgA nephropathy (IgAN) predominately arises in young adults and can progress to chronic kidney disease (CKD) and, ultimately, kidney failure or death.While there are guidelines for treating IgAN, there are still unanswered questions around the condition, including when patients are referred for specialist care, what their health-related quality of life (HRQoL) is, and what other factors may be involved in progression to CKD.These questions were investigated, and findings shown, in three posters presented at the 61 st European Renal Association (ERA) Congress in Stockholm, Sweden.The first poster, which surveyed Europebased physicians who treated at least 50 patients with Stage 1-4 CKD, found that nearly a third of patients were referred to them later than they should have been, given their IgAN symptoms.The survey also revealed that, while over three-quarters of patients were in CKD Stage 3 or above, the majority of physicians (98%) rated a patient's overall health as good or excellent.In the second poster, both patients and These presentations took place virtually at the 61 st
Csomor et al. (Thu,) studied this question.